Abstract
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most common and fatal cancers with a heterogeneous incidence throughout different regions of the world [1] . HCC, whose incidence has been vigorously increasing in western coun tries, has the highest incidence in China, Middle Africa, and Japan. Epidemiology of HCC differs among different geographical regions. Hepatitis B and C are the main risk factors in Asia and Africa while alcohol intake is the main driving force in Europe and the United States [2] . Overall survival rate of HCC patients is very low due to inefficient treatment options. HCC is resistant to most of the conventional therapies, thus the only plausible treatment is liver transplantation that is restricted to earlydiagnosed cases [3] . In order to provide a more effective therapeutic approach to HCC patients, genetic mechanisms underlying liver carcinogenesis have been studied for years; however, most of the mutations identified so far are "loss-of-function" type, thus they are not suitable to be used for targeted therapy [4] . The only molecularly targeted drug for HCC treatment is Sorafenib whose efficacy is not satisfactory [5] . Tumor cells need to overcome the telomere shortening problem, one of the most crucial obstacles during the transformation process. This can be achieved either by up Cevik D et al . TERT mutations in liver cancer regulating telomerase activity or with alternative lengthening of telomeres [6] . Integration of hepatitis B viral DNA into the telomerase reverse transcriptase (TERT) gene is observed in HCC patients with hepatitis B viral (HBV) infection and considered found as one of the paths to increase telomere length [79] . However, there are many HCC cases without HBV involvement and in which telomere length is still an issue for those. Recently, many groups reported the presence of two frequent mutations in TERT promoter region in different tumors including HCC [1016] . These promoter mutations are claimed to upregulate the TERT transcription by creating a binding site for ETS (Etwenty six) [10] and ternary complex factor (TCF) transcription factors [11] . Reported HCC tumors with TERT promoter mutations were from United States [12] and France [15] and mutation frequencies were 44% and 59%, respectively. Highly frequent TERT mutations may serve not only as novel diagnostic markers but also as and potential therapeutic targets for HCC. However, it is still unknown whether TERT promoter mutations occur in diverse HCCs worldwide, regardless of their geographical origin. As these tumors occur less frequently in western populations, but quite commonly then in Asian and African, TERT promoter status in Asian and African HCC patients is worth to know. In this study, we analyzed 15 HCC cell lines, as well as 44 HCC tumors from three different continents in search for two hotspot mutations in TERT promoter.
MATERIALS AND METHODS

Ethics and patient tissues
We used archival HCC tumor DNA samples (n = 44) that have been described previously in terms of hepatitis B viral DNA testing, TP53 mutations and murine double minute 2 (MDM2) polymorphism [17, 18] .
Cell lines
Huh7, HepG2, Hep3B, Hep40, PLC/PRF/5, FOCUS, Mahlavu, FLC4, and SKHEP1 cells were cultured in Dulbecco's modified Eagles medium, whereas SNU182, SNU387, SNU398, SNU423, SNU449, and SNU475 cell lines are grown in RPMI. Both media were supplemented with 10% fetal calf serum, 2 mmol/L Lglutamine, 1 × non essential amino acids, and 100 units of penicillin/ streptomycin (all from Life Technologies™). Cells were grown up to 70% confluency before genomic DNA extraction.
Mutation analysis by nucleic acid sequencing
Genomic DNA samples were isolated by using Purelink Genomic DNA Kit (Life Technologies™) according to manufacturer's instructions, then DNA concentrations were measured with Nanodrop Spectrometer (Thermo Scientific). 100 ng of genomic DNA was used to amplify a 474 bp region of TERT promoter flanking hotspot mutations that are found at positions 1295228 and 1295250 of chromosome 5 by using AccuPrime GCrich DNA Table 1 Telomerase reverse transcriptase promoter mutations in hepatocellular carcinoma cell lines polymerase kit (Life Technologies™) with forward primer 5'ACGAACGTGGCCAGCGGCAG3' and reverse primer 5' CTGGCGTCCCTGCACCCTGG3' [11] . Amplicons were sequenced with Sanger technique, and data were analyzed with DNADynamo software (BlueTractor Software Ltd) by comparing TERT sequence from UCSC Genome Browser as a reference.
Statistical analysis
Fisher exact test was used to compare statistical differences (Pvalues; onetailed) among clinical samples holding and lacking TERT promoter mutation using Wassar Statistics Tool available online (http://vassarstats.net). A Pvalue of less than 0.05 was considered to be significant.
RESULTS
TERT promoter mutations are frequently observed in hepatocellular carcinoma cell lines
We tested a panel of 15 HCC cell lines composed of six epitheliallike (Huh7, HepG2, Hep3B, Hep40, PLC/ PRF/5, and FLC4) and nine mesenchymallike (FOCUS, Mahlavu, SNU182, SNU387, SNU398, SNU423, SNU449, and SNU475, SKHEP1) cell types [19] for mutations at TERT gene promoter. Nine cell lines carried C228T mutation but only one cell line, Mahlavu, carried C250T mutation; all mutations were heterozygous (Table 1) . Two examples of sequence chromatograms representing C228T and C250T mutations are given in Figure 1 . In sum, 67% (10 out of 15) of HCC cell lines displayed a TERT promoter mutation. In all HCC cell lines tested, C228T and C250T mutations were found in a mutually exclusive manner. Both epitheliallike and mesenchymal like cells had these mutations with similar frequencies (4 out of 6, and 6 out of 9 respectively). We concluded that TERT promoter mutations occur frequently in HCC cell lines, regardless of their differentiation status.
TERT promoter mutations in primary hepatocellular carcinoma tumors
To determine TERT promoter mutation frequency in HCC tumors, we tested an archival collection of 44 HCC tumor DNAs (Table 2) collected from different countries around the world including Japan (11 patients), China (8), Germany (7), France (2), Israel (1), Mozambique (6), Transkei (4), Lesotho (2), Swaziland (1), and South Africa (2). Based on tumor viral DNA testin [16, 17] the etiology for 23 out of 44 (52.3%) of these tumors was hepatitis B virus infection. The etiology of other tumors was unknown. We identified 15 mutations in 44 tumors, 10 of 313 January 7, 2015|Volume 21|Issue 1| WJG|www.wjgnet.com Table 2 Telomerase reverse transcriptase promoter mutation analysis of hepatocellular carcinoma tumors which were C228T and the other 5 were C250T mutations. C228T mutations (23%) were again more frequent than C250T mutations (11%) and they were mutually exclusive, as observed in HCC cell lines (Table 2) . Figure 2 displays the distribution of TERT mutations in different continents. Tumors from Africa with the highest mutation frequency (53%) were followed by tumors from Europe (30%) and Asia (21%), respectively. We were not able to test whether these mutations were germ line or somatically acquired, however, all reported C228T and C250T mutations in HCC were acquired somatic mutations [12, 15] . Thus; we assume that mutations reported here are also somatic. Table 3 compares patient characteristics such as gender, age, geographical status, tumor HBV DNA and TP53 mutation as well as patient MDM2 single nucleotide polymorphism (SNP) 309 status with the mutational status of TERT promoter. There was no significant difference found in patient gender and age, but a weak association (P = 0.056) was found in geographical origin. Tumors from African patients displayed TERT promoter mutations twofold more frequently (53%) than nonAfrican patients (24%). Tumors with HBV DNA displayed less frequent 
Association of TERT promoter mutations with geographical origin of tumors and MDM2 SNP 309 polymorphism
Table 3 Characteristics of the patients according to telomerase reverse transcriptase promoter mutation status n (%)
TERT promoter mutations (26%) as compared to HBV negative tumors (39%), but the difference did not reach to a significance (P = 0.295). Similarly, tumors with wildtype TP53 displayed less frequent TERT promoter mutations (29%) as compared to those with a mutation (50%). However, this difference did not reach to a significant level (P = 0.280). In contrast, we found a week association between TERT promoter mutations and MDM2 SNP 309 TG polymorphism (P = 0.058). Patients with SNP309 TT polymorphism displayed 44% TERT promoter mutation, in contrast to those with TG polymorphism which displayed only 13% TERT promoter mutations. Indeed, TERT promoter mutations were over 3fold more frequent in patients with MDM2 SNP 309 TT status, than those with a TG status.
DISCUSSION
The TERT gene, encoding the catalytic subunit of telo merase reverse transcriptase enzyme, is a limiting factor for unlimited proliferation of most human somatic cells including hepatocytes. Lack of TERT gene expression in these cells leads to a progressive erosion of telomeres during successive cell divisions culminating with a permanent cell cycle arrest when telomere DNA reaches a critically short stature. Cancer cells such as HCC cells overcome this arrest by reactivating TERT gene expression with illknown mechanisms. TERT reactivation is so far the most frequently observed (80%90%) aberration in HCC tumors [20, 21] . Several mechanisms have been reported for the activation of TERT expression in cancer cells, including myc and Wnt/βcatenin signalingmediated activation [2224] , alternative splicing, and epigenetic alterations [25, 26] . Whether these mechanisms are involved in hepatocellular carcinogenesis is still unknown.
TERT reactivation is associated with HBV DNA inte gration near the TERT gene in rare cases of HCC, providing a clue about viral reactivation of TERT expression [7] . In addition, TERT promoter mutations have been reported recently as frequent events in some cancers such as melanoma, sarcomas, urothelial carcinoma, bladder cancer, glioblastoma, thyroid cancer, and HCC [1016] . Although it is not clear yet whether such mutations are necessary and sufficient for TERT reactivation in cancer cells, it appears that somatic mutations of TERT promoter are among the most frequent aberrations observed in some tumor types. Our studies in HCC cell lines reiterate this striking finding. With 60% frequency, TERT mutation is the most frequent mutational event observed in these cell lines together with TP53 mutations so far [27] . Thus, it is very likely that TERT promoter mutations facilitate the establishment of HCC cell lines by overcoming telomere shortening during in vitro culture. We have found similar mutation frequencies for both epithelial like and mesenchymallike cell lines suggesting that mutagenesis of the TERT promoter is independent of the differentiation status of the cell lines. Early HCCs display epithelial like morphology whereas advanced HCCs may display mesenchymallike morphology associated with epithelial to mesenchymal transition that is often observed during tumor progression [28, 29] . Our findings suggest that TERT mutations are early events during hepatocellular carcinogenesis in confirmation with a recent report [15] . The mutations observed in cell lines are the same type of mutations observed in primary tumors. This suggests that cell line mutations did not occur spontaneously during cell culture. Their high frequency may indicate that tumor cells with such mutations are established more easily.
TERT promoter mutations that are observed in 34% of primary HCC tumors are quite high, albeit less frequent than those observed in cell lines. This lower frequency in tumors may be expected because of the potential bias due to a selective advantage during cell culture as stated above. Additionally, heterozygous TERT promoter mutations may be more difficult to detect due to the contamination of tumor DNA with the DNA coming from noncancer cells into tumor tissues. Despite these limitations, the existence of TERT promoter mutations in at least onethird of primary tumors indicates that this gene is one of the most frequent targets for mutation in liver cancer. Our recently published findings pinpointed TERT as a critical gene involved in HCC cell immortality, which itself is viewed as a central mechanism of hepatocellular carcinogenesis in humans [30, 31] . This present study, together with a recent study [15] clearly establishes that TERT promoter mutation is a hallmark of liver cancer. Our findings provide further evidence for a global incidence of TERT promoter mutations in liver cancer regardless of their geographical origin. Moreover, we provide preliminary evidence for a higher frequency of these mutations in patients from Africa. Thus TERT mutations restricted to two hotspots at its promoter, are universal markers for liver cancer and thus they may serve as easy cancer biomarkers in high risk populations such as those chronically infected with hepatitis viruses, as well as cirrhosis. Finally, higher manifestation of TERT promoter mutations in HCC patients with MDM2 SNP309 TG status strongly suggests that there is a cross talk between TP53-MDM2 axis and TERT functions in liver cancer. Further research is needed to confirm these initial observations.
In conclusion, TERT promoter mutations that are widely observed in liver cancers from around the world provide sufficient evidence for the critical role of telomere biology and cellular immortality in these cancers.
COMMENTS
Background
Hepatocellular carcinoma (HCC) is one of the most fatal cancers over the world with an increasing incidence in western countries, so it is of great importance to reveal genetic mechanisms that may play an important role in liver tumor formation. Telomeres are repetitive DNA sequences found at both ends of each chromosome. In normal somatic cells, they get shorter after each cell division and cells can no longer divide when telomere length becomes too short. Tumor cells require mechanisms to overcome telomere shortening problem to be able to divide infinitely. One way to solve telomere shortening problem is to reactivate telomerase reverse transcriptase (TERT) to synthesize telomeric DNA and prevent telomeres from shortening. TERT may be activated via promoter mutations. Here we determine mutation status of TERT promoter in established liver cancer cell lines and patient tumor samples.
Research frontiers
TERT promoter mutations have first been defined in melanoma and they are claimed to create new binding sites for specific transcription factors and increase TERT expression. This may be used by tumor cells as a mechanism to overcome telomere shortening problem so it is important to show the presence of the same mutations in the promoter region of TERT and determine their frequencies in HCC. Deficiencies of early diagnosis and systemic therapy of liver cancer are the major causes of its high mortality. Screening of TERT promoter status may help early diagnosis of tumor formation in patients with chronic liver disease. In addition, targeting of TERT promoter mutations may open new horizons for specific therapies of liver cancer.
Innovations and breakthroughs
Telomerase reactivation is common to liver cancer samples, and TERT promoter mutations have been reported recently. Tumor samples were collected from hospitals from counties such as France and United States, where liver cancer is not a major disease contrary to some other countries located in Asia (China and Japan) and Africa (southern African countries) with a very high incidence. Thus, it was not clear how common TERT promoter mutations were over the world, especially in Africa and Asia. In this present study, we tried to show that TERT promoter mutations are common in hepatocellular carcinoma (HCC), regardless of geographical location. Moreover, this research showed that HCCs from Africa are more likely to carry TERT promoter mutations, in comparison with Non-African tumors.
Applications
The high frequency of TERT promoter mutations resulting from the present study suggests that these mutations are critical or may be necessary for liver tumor formation. Therefore, they can be used for diagnostic or prognostic purposes for patient care. Furthermore, if such mutations are causing tumorspecific reactivation of telomerase activity, they may serve as tumor-selective targets for novel therapies.
Terminology
Hepatocellular carcinoma is a primary liver cancer. Telomeres are DNA sequences located on the tips of chromosomes. TERT gene encodes for an enzyme responsible for the synthesis of telomeric DNA.
